Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. — Stella

Home/Marginal Zone Lymphoma (MZL)/

View on ClinicalTrials.gov

Recruiting

Back to Marginal Zone Lymphoma (MZL) trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu

Key details

Phase

Safety & dosing

Sponsor

The First Affiliated Hospital of Soochow University

Enrollment target

~23 participants

Started

October 2025

Primary completion

April 2028

Age range

18 Years and older

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.